Joseph M. Limber Appointed to XOMA Corp. (XOMA) Board of Directors

XOMA, a leader in the discovery and development of therapeutic antibodies, announced that Mr. Joseph M. Limber has been appointed to its Board of Directors.

“I am pleased to welcome Joe to our Board of Directors,” remarked John Varian, XOMA’s Chief Executive Officer. “Our team is particularly excited to work closely with Joe, as he has successfully developed markets for specialty pharmaceutical products and managed the critical transition from research organization to commercial entity. We expect to make the same transition in the coming years and Joe’s insight and guidance while we prepare for a gevokizumab commercial launch will be instrumental to our future success.”

With a career that spans over 30 years, Mr. Limber brings unparalleled biotechnology and corporate leadership experience to the Board. His current position as President and CEO at Prometheus Laboratories, a Nestle Health Science company, has positioned him to bring a new and unique perspective to XOMA’s board.

In the almost 10 years he has spent with Prometheus, Mr. Limber led a significant expansion of its business, both organically through internally developed products and through product acquisitions. He led negotiations to acquire exclusive U.S. commercial rights to ENTOCORT EC from AstraZeneca and Proleukin from Novartis, as well as the purchase of Lotronex from GlaxoSmithKline. Mr. Limber’s leadership helped Prometheus Laboratories grow its revenues to over $500 million.

Prior to Prometheus, Mr. Limber was a consultant and interim CEO of Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. He also served as President and CEO of ACLARA BioSciences, Inc., a developer of assay technologies and lab-on-a-chip systems for life science research, for four years, from 1998-2002. From 1996 to 1998, he was the President and COO of Praecis Pharmaceuticals, a biotechnology company focused on the discovery and development of pharmaceutical products.

Mr. Limber also served as Executive Vice President of SEQUUS Pharmaceuticals, Inc., in addition to management positions in marketing and sales with Syntex Corporation and with Ciba-Geigy Corporation. Mr. Limber has held seats on the Boards of Directors at numerous companies, including Panacos Pharmaceuticals, Molecular Insight Pharmaceuticals, and CombiMatrix Corporation.

For more information, visit www.XOMA.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html